Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

NIAID launches first Phase II trial of a ’global’ HIV/AIDS vaccine

12.10.2005


A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants at sites in Africa, North America, South America and the Caribbean to test the safety and immune response to the vaccine.



The experimental vaccine was developed by scientists at NIAID’s Dale and Betty Bumpers Vaccine Research Center (VRC) and is being studied in the HIV Vaccine Trials Network (HVTN), a clinical research collaboration funded by NIAID’s Division of AIDS (DAIDS).

"This trial marks an important step in the advancement toward an AIDS vaccine. The rapid development of this candidate vaccine--less than five years since the launch of the VRC--underscores our commitment to hasten the day when we have an effective AIDS vaccine," says NIAID Director Anthony S. Fauci, M.D.


The unique vaccine combines synthetically modified elements of four HIV genes found in subtypes A, B and C of the virus--the subtypes commonly found in Africa, the Americas, Europe and parts of Asia. These subtypes represent about 85 percent of HIV infections worldwide.

"This is the first Phase II study of a vaccine candidate that is broadly relevant to the global AIDS pandemic because it combines components of HIV strains found throughout the world," says VRC Director Gary Nabel, M.D., Ph.D. "We look forward to working with our partners in the United States and abroad as we take this vaccine into the next phase of clinical evaluation."

The trial, known as HVTN 204, is being coordinated with two other planned clinical studies, an unprecedented collaboration among researchers in three clinical trial networks and NIAID. The International AIDS Vaccine Initiative plans to conduct a Phase I study of the VRC vaccine at sites in Kenya and Rwanda, and the U.S. Military HIV Research Program plans Phase I and II studies at sites in Uganda, Kenya and Tanzania; the studies are contingent on the appropriate regulatory and ethical approvals being granted in these countries.

About the Vaccine

The three harmonized trials will be testing a "prime-boost" strategy composed of two vaccine components given at different times. Both contain synthetic versions of four HIV genes: gag, pol, nef and env. The gag, pol and nef genes come from HIV subtype B, the primary virus found in Europe and North America. Env, the fourth gene, codes for an HIV coat protein that allows the virus to recognize and attach to human cells. The vaccine incorporates modified env genes from subtypes A and C, most common in Africa and parts of Asia, as well as subtype B.

The two vaccine components differ in how the genes are packaged. One contains only the naked gene fragments, which cannot reconstitute into an infectious virus. The other uses a weakened type of respiratory virus known as adenovirus as a vector to shuttle the non-infectious gene fragments into the body.

Adenoviruses cause upper respiratory tract illness, such as the common cold. However, because the vaccine contains only HIV gene fragments housed in an adenovirus that cannot replicate, study participants cannot become infected with HIV or get a respiratory infection from the vaccine.

"The use of adenovirus vectors appears to be the most promising advance in recent years in the search for an HIV vaccine," says Peggy Johnston, Ph.D., director of the Vaccine and Prevention Research Program in DAIDS, NIAID. Lawrence Corey, M.D., principal investigator of the HVTN, adds, "We are excited to work with the VRC on this new vaccine candidate. This prime-boost approach incorporating adenovirus vector seems to generate the type and quantity of immune responses we feel will be necessary to impact an infection like HIV. This study will define more completely the levels of immunity this novel approach will achieve in a broad range of people."

The DNA components of the vaccine were manufactured by the San Diego-based Vical, Inc. The adenovirus vector was developed by VRC in collaboration with GenVec Inc., of Gaithersburg, Md., which also manufactured the adenovirus vector vaccine.

HVTN 204 Study Details

The HVTN 204 Phase II study will test the safety and ability of the vaccine to generate an immune response in 480 healthy, HIV-negative adults ages 18 to 50. The researchers plan to recruit volunteers from populations particularly hard-hit by AIDS, including African Americans and other ethnic minorities.

The study is being led by Michael Keefer, M.D., of the University of Rochester, NY, and Gavin Churchyard, M.B.B.Ch., F.C.P., M.Med., Ph.D., of Aurum Health Research Ltd. in South Africa.

The trial opened at the University of Alabama at Birmingham and is designed to include 13 HVTN sites, provided that regulatory and ethical approval is granted at each site:

  • North America--Baltimore, MD; Boston, MA; Providence, RI; Birmingham, AL; Nashville, TN; and Rochester, NY
  • South America--Rio de Janeiro and São Paulo, Brazil
  • Caribbean--Port-au-Prince, Haiti; Kingston, Jamaica
  • Africa--Gaborone, Botswana; and Cape Town, Soweto, and KOSH (Klerksdorp, Orkney, Stilfontein, and Hartbeesfontein), South Africa

Half of the 480 trial participants will be enrolled in the Americas (Haiti, Jamaica, Brazil and the United States) and half in southern Africa (Botswana and South Africa). The geographic diversity of participants allows the researchers to evaluate whether the immune responses generated to the vaccine vary according to the amount of prior exposure to adenovirus, as measured by pre-existing levels of adenovirus antibodies. Africans, for example, generally have had greater exposure to adenovirus than people living in North America.

The participants, divided into two groups, will receive four injections spread out over a period of six months. One group will receive three injections of the naked DNA component followed by a booster injection of the adenoviral vector component. The second group will receive four injections of a placebo vaccine consisting of sterile saltwater. Because the study is "double blind," neither the participants nor the researchers will know whether a volunteer is receiving the study vaccine or the placebo until the end of the trial.

NIAID News Office | EurekAlert!
Further information:
http://www.niaid.nih.gov
http://www.hvtn.org

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>